Author(s): Rashmi K. Ambasta*,$, Ira Dave* and Pravir Kumar*,#
Journal: Journal of Pharmacy Research
ISSN 0974-6943
Volume: 4;
Issue: 10;
Start page: 3568;
Date: 2011;
Original page
Keywords: Somatic mutation | Cancer Genome Project (CGP) | Phosphatase and tensin homolog
ABSTRACT
The ongoing Cancer Genome Project (CGP) aims at sequencing the genes with the mutations which cause cancer. In this review, we aim to simplify the informationgiven in the COSMIC (Catalogue of somatic mutation in cancer). PTEN (Phosphatase and tensin homolog) is a tumor suppressor gene and is involved in manycellular functions. The mutation in PTEN has been seen in many cancers and especially it is seen in high incidence in endometrial cancer, central nervous systemcancer, prostate cancer etc. The analysis is based on the data given in the COSMIC database. PTEN mutation, although has been found in cancers but in CGP drugsensitivity project, no drug has been till date targeted. This may be due to lack of enough research on PTEN or proper data analysis has not been done. Thus thisreview gives an insight of how PTEN can also be a potential drug target. In this review mutations have been grouped in different type of cancers, which makes iteasier to infer data and statistics. This in turn gives an easy and comprehensive reference to the data which can be used for future research.
Journal: Journal of Pharmacy Research
ISSN 0974-6943
Volume: 4;
Issue: 10;
Start page: 3568;
Date: 2011;
Original page
Keywords: Somatic mutation | Cancer Genome Project (CGP) | Phosphatase and tensin homolog
ABSTRACT
The ongoing Cancer Genome Project (CGP) aims at sequencing the genes with the mutations which cause cancer. In this review, we aim to simplify the informationgiven in the COSMIC (Catalogue of somatic mutation in cancer). PTEN (Phosphatase and tensin homolog) is a tumor suppressor gene and is involved in manycellular functions. The mutation in PTEN has been seen in many cancers and especially it is seen in high incidence in endometrial cancer, central nervous systemcancer, prostate cancer etc. The analysis is based on the data given in the COSMIC database. PTEN mutation, although has been found in cancers but in CGP drugsensitivity project, no drug has been till date targeted. This may be due to lack of enough research on PTEN or proper data analysis has not been done. Thus thisreview gives an insight of how PTEN can also be a potential drug target. In this review mutations have been grouped in different type of cancers, which makes iteasier to infer data and statistics. This in turn gives an easy and comprehensive reference to the data which can be used for future research.
